Scripps Florida Logo

Solt Lab Publications

[Last updated 8/25/17]

Sun Y, Liu CH, Wang Z, Meng SS, Burnim SB, SanGiovanni JP, Kamenecka TM, Solt LA, Chen J. RORα modulates semaphorin 3E transcription and neurovascular interaction in pathological retinal angiogenesis. FASEB J. 2017, Jun 23.

Amador A, Huitron-Resendiz S, Roberts AJ, Kamenecka TM, Solt LA, Burris TP.  Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation. PLoS One. 2016 Sep 7;11(9).

de Vera IM, Giri PK, Munoz-Tello P, Brust R, Fuhrmann J, Matta-Camacho E, Shang J, Campbell S, Wilson HD, Granados J, Gardner WJ Jr, Creamer TP, Solt LA, Kojetin DJ.  Identification of a Binding Site for Unsaturated Fatty Acids in the Orphan Nuclear Receptor Nurr1. ACS Chem Biol. 2016 Jul 15;11(7):1795-9. 

Amador A, Wang Y, Banerjee S, Kameneka TM, Solt LA, Burris TP.  Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression.  PLoS One. 2016 Mar 10;11(3).

Wang R, Solt LA.  Metabolism of murine TH 17 cells: Impact on cell fate and function.  Eur J Immunol. 2016 Apr 46(4):807-16.

Sun Y, Liu CH, SanGiovanni JP, Evans LP, Tian KT, Zhang B, Stahl A, Pu WT, Kamenecka TM, Solt LA, Chen J.  Nuclear receptor RORα regulates pathologic retinal angiogenesis by modulating SOCS3-dependent inflammation.  Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10401-6.

Solt LA, Burris TP.  Th17 cells in Type 1 diabetes: a future perspective.  Diabetes Manag (Lond). 2015 Jul;5(4):247-250.

Flaveny CA, Griffett K, El-Gendy Bel-D, Kazantzis M, Sengupta M, Amelio AL, Chatterjee A, Walker J, Solt LA, Kamenecka TM, Burris TP. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.  Cancer Cell. 2015 Jul 13;28(1):42-56.

Sitaula S, Billon C, Kamenecka TM, Solt LA, Burris TP.  Suppression of atherosclerosis by synthetic REV-ERB agonist.  Biochem Biophys Res Commun. 2015 May 8;460(3):566-71.

Solt LA, Banerjee S, Campbell S, Kamenecka TM, Burris TP.  ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes.  Endocrinology. 2015 Mar;156(3):869-81.

Banerjee S, Wang Y, Solt LA, Griffett K, Kazantzis M, Amador A, El-Gendy BM, Huitron-Resendiz S, Roberts AJ, Shin Y, Kamenecka TM, Burris TP.  Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour.  Nat Commun. 2014 Dec 23;5:5759.

Matta-Camacho E, Banerjee S, Hughes TS, Solt LA, Wang Y, Burris TP, Kojetin DJ.  Structure of REV-ERBβ ligand-binding domain bound to a porphyrin antagonist.  J Biol Chem. 2014 Jul 18;289(29):20054-66.

Gray CM, Remouchamps C, McCorkell KA, Solt LA, Dejardin E, Orange JS, May MJ.  Noncanonical NF-κB signaling is limited by classical NF-κB activity.  Sci Signal. 2014 Feb 4;7(311):ra13.

Woldt E, Sebti Y, Solt LA, Duhem C, Lancel S, Eeckhoute J, Hesselink MK, Paquet C, Delhaye S, Shin Y, Kamenecka TM, Schaart G, Lefebvre P, Nevière R, Burris TP, Schrauwen P, Staels B, Duez H.  Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy.  Nat Med. 2013 Aug;19(8):1039-46.

Kumar N, Nuhant P, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, Ruben DGO, Burris TP, Cameron M, Mercer BA, Hodder P, Roush WR, Rosen H, Griffin PR.  Identification of a novel selective inverse agonist probe and analogs for the Retinoic acid receptor-related Orphan Receptor Alpha (RORα).  Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.2010 Sep 1 [updated 2013 Mar 14].

Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K, Lundasen T, Hughes T, Kojetin DJ. Nuclear receptors and their selective pharmacologic modulators.  Pharmacol Rev. 2013 Mar 1;65(2):710-78.

Griffett K, Solt LA, El-Gendy Bel-D, Kamenecka TM, Burris TP.  A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol. 2013 Mar 15;8(3):559-67. 

Solt LA, Kamenecka TM, Burris TP.  LXR-mediated inhibition of CD4+ T helper cells. PLoS One. 2012;7(9):e46615.

Solt LA, Burris TP.  Action of RORs and their ligands in (patho)physiology. Trends Endocrinol Metab. 2012 Dec;23(12):619-27.

Solt LA, Kumar N, He Y, Kamenecka TM, Griffin PR, Burris TP.  Identification of a selective RORγ ligand that suppresses T(H)17 cells and stimulates T regulatory cells. ACS Chem Biol. 2012 Sep 21;7(9):1515-9. 

Wang Y, Solt LA, Kojetin DJ, Burris TP.  Regulation of p53 stability and apoptosis by a ROR agonist. PLoS One. 2012;7(4):e34921.

Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, Yoo SH, Takahashi JS, Butler AA, Kamenecka TM, Burris TP.  Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012 Mar 29;485(7396):62-8.

Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, Kamenecka TM, Griffin PR.  Identification of SR2211: a potent synthetic RORγ-selective modulator. ACS Chem Biol. 2012 Apr 20;7(4):672-7.

Doerdelmann T, Kojetin DJ, Baird-Titus JM, Solt LA, Burris TP, Rance M.  Structural and biophysical insights into the ligand-free Pitx2 homeodomain and a ring dermoid of the cornea inducing homeodomain mutant. Biochemistry. 2012 Jan 17;51(2):665-76.

Begriche K, Levasseur PR, Zhang J, Rossi J, Skorupa D, Solt LA, Young B, Burris TP, Marks DL, Mynatt RL, Butler AA.  Genetic dissection of the functions of the melanocortin-3 receptor, a seven-transmembrane G-protein-coupled receptor, suggests roles for central and peripheral receptors in energy homeostasis. J Biol Chem. 2011 Nov 25;286(47):40771-81.

Solt LA, Kojetin DJ, Burris TP.  The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis.  Future Med Chem. 2011 Apr;3(5):623-38.

Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka TM, Roush WR, Vidović D, Schürer SC, Xu J, Wagoner G, Drew PD, Griffin PR, Burris TP.  Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011 Apr 28;472(7344):491-4.

Kumar N, Kojetin DJ, Solt LA, Kumar KG, Nuhant P, Duckett DR, Cameron MD, Butler AA, Roush WR, Griffin PR, Burris TP.  Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist. ACS Chem Biol. 2011 Mar 18;6(3):218-22.

___________

Home
___________

Lab Members
___________

Publications
___________

Funding
___________

Positions
___________

Life in Jupiter
___________

In the Press
___________

Support Us
___________

Contact Us
___________